Winmark Full Year 2024 Earnings: In Line With Expectations
Revenue: US$81.3m (down 2.3% from FY 2023).
Net income: US$40.0m (flat on FY 2023).
Profit margin: 49% (in line with FY 2023).
EPS: US$11.36 (down from US$11.55 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
The primary driver behind last 12 months revenue was the Franchising segment contributing a total revenue of US$79.5m (98% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$24.3m (64% of total expenses). Explore how WINA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Specialty Retail industry in the US.
Performance of the American Specialty Retail industry.
The company's share price is broadly unchanged from a week ago.
We should say that we've discovered 3 warning signs for Winmark (1 can't be ignored!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
AlbaCore Capital Brings Aboard Diarmuid Curran to Enhance European CLO Capabilities
LONDON--(BUSINESS WIRE)--European credit specialist, AlbaCore Capital Group ('AlbaCore'), has announced the appointment of Diarmuid Curran as Managing Director and Portfolio Manager. Diarmuid Curran has joined AlbaCore as Managing Director and Portfolio Manager, bringing a wealth of experience in European credit markets to further strengthen the team and support the continued growth of the firm's European CLO platform. Diarmuid will focus on AlbaCore's leading European CLO platform – both new issuance and existing CLO fund management, reporting to Deborah Cohen Malka, Partner and Portfolio Manager, who leads the CLO business. 'I'm pleased to welcome Diarmuid to the team at AlbaCore,' said Deborah Cohen Malka. 'His background and experience will strengthen our capabilities as we continue to take advantage of the pipeline of opportunities in Europe on behalf of our investor base.' Diarmuid joins AlbaCore from Napier Park Global Capital, where he served as a Portfolio Manager. In that capacity, he was responsible for managing a portfolio of European loans and High Yield bonds held in CLOs as well as credit selection and underwriting as a member of the Investment Committee. 'I've been impressed from afar by AlbaCore's reputation in the European market,' said Diarmuid Curran. 'I look forward to working with Deborah and the team to build upon their well-established European CLO business.' In March of this year, AlbaCore successfully priced AlbaCore Euro CLO VII - it's 7 th CLO – bringing the total value of CLO platform assets under management to c. €2.9 billion. The CLO platform incorporates negative ESG screening criteria in combination with AlbaCore's fundamental research and risk focused ESG considerations, including restrictions on the industries in which the CLO can invest. About AlbaCore Capital Group AlbaCore Capital Group is one of Europe's leading alternative credit specialists, investing in private capital solutions, direct lending, opportunistic and dislocated credit, CLOs, and structured products. Founded in 2016, AlbaCore is part of the First Sentier Investors Group. AlbaCore's investment philosophy is focused on capital preservation and generating attractive risk adjusted returns through the cycle for its investors. AlbaCore manages US $10.0 billion in AuM3 as of 31 March 2025 on behalf of global pension funds, sovereign wealth funds, endowments, insurance companies, family offices and high net worths around the world.
Business Upturn
an hour ago
- Business Upturn
Hyland expands its presence in India with a new office in Hyderabad
This marks a significant milestone in the company's global expansion strategy; enables access to technical expertise while strengthening the company's ability to serve customers globally NEW DELHI and HYDERABAD, India , June 10, 2025 /PRNewswire/ — Hyland, the pioneer of The Content Innovation Cloud™, is celebrating the official opening of its new office in Hyderabad , marking a significant milestone in the company's global expansion strategy, and mission to deliver breakthrough innovations to customers across the Asia Pacific region. The grand opening ceremony, held on 9 June 2025 , was graced by the presence of the US Consul General for Hyderabad , Ms. Jennifer Larson . Located in the heart of Hyderabad's prestigious Hitech City, the new facility represents Hyland's strategic investment in advancing The Content Innovation Cloud and accelerating customer success throughout Asia Pacific . This expansion positions the company to leverage the region's exceptional talent pool to drive next-generation innovations that transform how organizations manage, process, and unlock value from their content. ' Hyderabad's world-class technology ecosystem makes it the ideal location to advance The Content Innovation Cloud and deliver transformative solutions to our Asia Pacific customers,' said Tim McIntire , CTO at Hyland. 'This expansion directly supports our innovation agenda, enabling us to develop cutting-edge capabilities that help customers streamline operations, enhance productivity, and drive digital transformation. We're honored to have US Consul General Jennifer Larson join us for this momentous occasion, highlighting the power of US-India partnerships in advancing technological innovation.' The Hyderabad office will serve as a hub for innovation and customer success, housing critical functions focused on advancing The Content Innovation Cloud and delivering exceptional customer outcomes. This will drive product development, enhance customer enablement programs, and expand support capabilities to ensure Asia Pacific customers maximize value from Hyland's platform and solutions. The new facility is actively recruiting top talent to fuel Hyland's innovation engine across several key areas: Software Development professionals to architect and build next-generation capabilities within The Content Innovation Cloud to architect and build next-generation capabilities within The Content Innovation Cloud Professional Services specialists to accelerate customer implementations and drive successful digital transformation initiatives to accelerate customer implementations and drive successful digital transformation initiatives Customer Success coordinators to ensure customers achieve measurable business outcomes and maximize their return on investment to ensure customers achieve measurable business outcomes and maximize their return on investment Cloud and Technical Support experts to deliver world-class support and optimize customer experiences across cloud environments Hyland's new Hyderabad office joins its existing Kolkata location, reinforcing the company's global reach while creating significant employment opportunities, driving growth and customer success across the APAC region. To explore Hyland career opportunities in India , please visit the company's careers page at About Hyland Hyland empowers organizations with unified content, process and application intelligence solutions, unlocking profound insights that fuel innovation. Trusted by thousands of organizations worldwide, including many of the Fortune 100, Hyland's solutions fundamentally redefine how teams operate and engage with those they serve. For more information on Hyland, our products and solutions, please visit Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
an hour ago
- Business Wire
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion," said Mike Blue, President and CEO, HistoSonics. The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit:
